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Summary
Background Radiation therapy (RT) has a suboptimal effect in patients with pancreatic ductal adenocarcinoma
(PDAC) due to intrinsic and acquired radioresistance (RR). Comprehensive bioinformatics and microarray analysis
revealed that cholesterol biosynthesis (CBS) is involved in the RR of PDAC. We now tested the inhibition of the CBS
pathway enzyme, farnesyl diphosphate synthase (FDPS), by zoledronic acid (Zol) to enhance radiation and activate
immune cells.
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Methods We investigated the role of FDPS in PDAC RR using the following methods: in vitro cell-based assay,
immunohistochemistry, immunofluorescence, immunoblot, cell-based cholesterol assay, RNA sequencing, tumouroids (KPC-murine and PDAC patient-derived), orthotopic models, and PDAC patient’s clinical study.
Findings FDPS overexpression in PDAC tissues and cells (P < 0.01 and P < 0.05) is associated with poor RT
response and survival (P = 0.024). CRISPR/Cas9 and pharmacological inhibition (Zol) of FDPS in human and
mouse syngeneic PDAC cells in conjunction with RT conferred higher PDAC radiosensitivity in vitro (P < 0.05, P <
0.01, and P < 0.001) and in vivo (P < 0.05). Interestingly, murine (P = 0.01) and human (P = 0.0159) tumouroids
treated with Zol+RT showed a significant growth reduction. Mechanistically, RNA-Seq analysis of the PDAC xenografts and patients-PBMCs revealed that Zol exerts radiosensitization by affecting Rac1 and Rho prenylation, thereby
modulating DNA damage and radiation response signalling along with improved systemic immune cells activation.
An ongoing phase I/II trial (NCT03073785) showed improved failure-free survival (FFS), enhanced immune cell
activation, and decreased microenvironment-related genes upon Zol+RT treatment.
Interpretation Our findings suggest that FDPS is a novel radiosensitization target for PDAC therapy. This study
also provides a rationale to utilize Zol as a potential radiosensitizer and as an immunomodulator in PDAC and other
cancers.
Funding National Institutes of Health (P50, P01, and R01).
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Research in context
Evidence before this study
Pancreatic ductal adenocarcinoma (PDAC) patients typically respond to radiotherapy (RT) initially. However,
cancer cells eventually acquire radioresistance (RR)
through metabolic reprogramming of cholesterol biosynthesis pathway (CBS) genes, speciﬁcally, farnesyl
diphosphate synthase (FDPS). Thus, RT enhances FDPS
expression, which modulates Rac1 and DNA damage
signals and decreases the radio-responsiveness of PDAC
cells.
Added value of this study
Our study is the ﬁrst study to (1) investigate the role of
FDPS in PDAC radioresistance and poor survival, (2)
assess the utility of Zoledronic acid (Zol), a speciﬁc
inhibitor of FDPS, conferred signiﬁcant radiosensitization effects in PDAC cells, 3D murine KPC, and human
PDAC tumouroids and in vivo models, and (3) our preclinical and ongoing clinical study evaluating the safety
and efﬁcacy of Zol as a radiosensitizer will provide proof
of principle for FDPS as a novel target for radiosensitization with a deﬁned underlying mechanism. Furthermore, we show that Zol+RT treatment showed excelled
tumour pathological response with an improved systemic immune cell activation and expanded variants of
gd T cells.
Implications of all the available evidence
Collectively, our study suggests that FDPS is a novel
radiosensitization target for PDAC. The presented work
also provides a solid rationale to investigate the use of
Zol as a potential radiosensitizer and immunomodulator
that can be exploited in conjunction with checkpoint
blockade agents to prevent radioresistance and
improve radiation therapy in other cancers.

Introduction
PDAC is the third most deadly disease and requires new
therapeutic strategies.1 Resection is the only curative
therapy for PDAC, but less than 20% of patients are eligible for resection at the time of diagnosis, with a fiveyear overall survival of 10%.2,3 Radiation therapy (RT) is
commonly used in the neoadjuvant setting and as consolidative therapy for patients with locally advanced diseases. Since recurrence rates after resection are high,
additional therapy is often considered, particularly in
the neoadjuvant setting. Thus, to improve survival in
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patients with PDAC, RT is frequently used alone and in
conjunction with chemotherapy before pancreatic surgery. However, 80% of PDAC patients fail to achieve an
objective response due to intrinsic and acquired radioresistance (RR).4 Furthermore, the role of radiosensitizing
chemotherapy remains controversial, and the optimal
regimen remains to be defined.5,6 Hence, there is an
unmet need to discover novel radiosensitizers to overcome RR and improve resectability and survival of
PDAC patients.
Previously, we identified the expression of several
cholesterol biosynthesis (CBS) and few fatty acid biosynthesis pathway genes, most notably FDPS, to be associated with RR in PDAC.7 FDPS is a crucial enzyme of
the mevalonate pathway that catalyzes the production of
geranyl pyrophosphate and farnesyl pyrophosphate
from isopentenyl pyrophosphate and dimethylallyl pyrophosphate. Importantly, increased expression of FDPS
was found to be associated with several malignancies,
such as prostate cancer, glioblastoma, colon cancer, and
PDAC.8!11 When FDPS is overexpressed in tumour tissues, its activity increases and correlates with activation
of growth-promoting signalling pathways such as AKT,
ERK, and STAT3.9 Similarly, forced overexpression of
FDPS in cancer cells resulted in activation of ERK and
AKT pathways in prostate cancer.8 A recent study investigated the ability of FDA-approved drugs to target CBS
pathway-associated proteins. In the screening, nitrogencontaining bisphosphonate, such as zoledronic acid
(Zol), was identified as a candidate inhibitor of FDPS.10
In preclinical 3D tumouroid models, treatment with Zol
attenuated tumouroid growth.8 Due to its inhibitory
effects on osteoclasts, Zol has been primarily investigated as a palliative treatment for cancers that are
related to bone (e.g., osteosarcomas), associated with
bone metastasis (e.g., breast, prostate, and lung), and
causing bone turnover (multiple myeloma).12!14 In
multiple myeloma, Zol was shown to reduce the risk
associated with mortality by 25%, along with a reduction
of skeletal-related events by 25%, compared with
pamidronate, another bisphosphonate approved for
multiple myeloma treatment.15
The objective of the current study was to test the
radiosensitization potential of Zol in PDAC cells, mouse
and patient-derived PDAC tumouroids, and in vivo
mouse models. Mechanistically, our RNA-Seq and in silico analysis demonstrate that Zol treatment impairs
expression of DNA damage and repair proteins, thereby
enhancing the radiosensitivity of PDAC cells. We also
validated that genetic and pharmacological disruption
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of FDPS sensitizes human and mouse PDAC to RT.
Further, we extended our in vitro and in vivo observations to clinical settings. In a phase I/II clinical trial, we
evaluated the safety and efficacy, of Zol concurrently
with hypofractionated RT/5FU or capecitabine in
patients with borderline resectable and locally advanced
PDAC and studies its impact on overall survival and surgical resection rate. We further characterized the Zolassociated tumour radiation response and imunomodulatory effects.

Methods
Ethics
Mouse studies were performed under our institutional
Animal Review Committee-approved protocol and
ARRIVE guidelines. The clinical trial is approved by the
Institution review board (IRB) of UNMC (IRB 552-16)
and is registered at clinicalTrials.gov (NCT03073785).
Written informed consent was obtained from all
patients after receiving induction chemotherapy FOLFIRINOX or gemcitabine/Abraxane.

Immunohistochemistry and immunoﬂuorescence
Human PDAC tissues were obtained from the UNMC
tissue bank with a previous history of radiation and chemotherapy treatment. Based on the pathological scoring, PDAC tissues were categorized as poor responders
with pathological scores 0-3, intermediate responders
(4-6), and good responders (7-9). Serial sections were
stained for FDPS (1:100, Proteintech, USA, 16129-1-AP)
and Ki67 antibodies and evaluated for percentage and
intensity of staining. The intensity of DAB (3, 3’-diaminobenzidine) staining was graded on a 0-3 (No or negative staining (0), weak (1), moderate (2), and high or
intense (3)) scoring system. The percentage of cells
staining was scored semi-quantitatively, ranging from 14, where 1-25% (1), 26!50% (2), 51-75%, and 76-100%
(4) as the maximum region of staining. Similarly, xenograft tissues were stained with Rad50, pP95, Ki67 rabbit
(1:100, Cell signaling technology # 9449), and cleaved
caspases-3 (1:200, Cell signaling technology # 9661)
specific antibodies and evaluated for staining as
described in our previous publications.7,8,16 For ferroptosis assessment, PDAC cells were seeded on sterile coverslips and treated with the indicated concentration of
Zol and/or RT. Lipid peroxidation was measured by
staining using C11 BODIPY, and immunofluorescence
images were taken using a laser-scanning confocal
microscope (LSCM).

Cell culture, reagents, and transfection
All the human and mouse PDAC cell lines were regularly inspected for mycoplasma contamination and
maintained in DMEM media supplemented with 10%
www.thelancet.com Vol xx Month xx, 2021

FBS and antibiotics penicillin (100 U/mL) and streptomycin (100 mg/mL) as described previously.7,16 Luciferase-tagged T3M4, CD18/HPAF, and AsPC-1 PDAC cells
human PDAC cell lines, HPNE normal immortalized
pancreatic cells, and CD18/HPAF ectopically overexpressed with constitutive active Rac1 mutant (Rac1G12V)
were provided by Dr. Ouellet (UNMC). Capan-1,
SW1990, BxPC-3, Suit-2, Colo-357, MIA PaCa, PDAC,
and normal immortalized ductal epithelial pancreatic
(HPDE) cells were purchased from American Type Culture Collection and routinely maintained in the laboratory. Mouse-derived syngeneic cell lines were derived
from the PDAC tumour-bearing mouse pancreas with
conditional activation of LSL-KrasG12D/+; LSLTrp53R172H/+; Pdx-1-cre, were maintained in a similar
complete media. The HPNE cell lines were maintained
in Keratinocyte medium supplemented with
0.05 mg/ml of bovine pituitary extract and 5 ng/ml of
EGF. All the cells were maintained as monolayers in the
media, as mentioned earlier, at 37°C with 5% CO2.

FDPS-targeting construct (gRNA and siRNA),
transfection, and zoledronic acid
Guide RNAs targeting FDPS were designed to the coding sequence of FDPS (ENST00000356657) corresponding to 1,555 bp encoding a protein of 419 amino
acids. Subsequently, the gRNAs were purchased from
GenScript. The construct bearing pSpCas9 BB-2A-GFP
(PX458) was transfected into T3M4 and CD18/HPAF
PC cell lines using Lipofectamine 2000 (Invitrogen,
CA, USA). Following multiple passages, GFP-positive
cells were flow-sorted, and clones were developed in 96well plates. Selected clones were validated for knockdown efficiency and pooled to obtain a heterogeneous
population for further analysis. For transient transfection studies, FDPS targeting siRNA (27 mer) and scramble siRNA was purchased from Origene8 and
transfected using lipofectamine 2000 reagent and incubated for 48 h. Zol was purchased from Sigma (St.
Louis, MO, USA) and was dissolved in sterile RNasefree water (Qiagen), aliquoted with a working solution
of 5-10 mM concentration, and stored at -20 °C.

Radiation treatment to PDAC cells
PDAC cells were irradiated using a linear accelerator in
the Department of Radiation Oncology at UNMC.
Radioselected radioresistant (RS-RR) subclones of
human PDAC cell lines (T3M4, CD18/HPAF, AsPC-1)
were generated from their parental cell lines by irradiating the cells using a fractionated irradiation dose of
approximately 2 Gy once a day for five days a week, over
a period of two weeks using the linear accelerator. Further, both parental control and RS-PDAC cells were
exposed to radiation sources with single doses of 0, 2.5,
5, and 7 Gy for the clonogenic survival assay. After
14 days of incubation, cells in the six-well plate were
3
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The sensitivity of human PDAC cells to irradiation was
measured using the clonogenic survival assay described
by Boothman et al.7,17 Cells were allowed to grow as a
monolayer to 40-60% confluency 24 h before radiation.
PDAC cells were seeded into a six-well plate in triplicate
at a plating density of approximately 2000 cells/well,
24 h before irradiation. The following day, cells were
treated with a single fraction of 0, 2.5, 5, and 7 Gy. The
cells were further allowed to grow for 14 days, and the
complete medium was changed every alternate day. The
endpoint for the clonogenic survival assay was determined by the number of colonies in cultures that were
not radiated. Large colonies consisting of 50 or more
cancer cells were considered a clone. After 14 days of
incubation, the cells were fixed with 100% methanol for
5 min and stained with 0.5% crystal violet in 25% methanol for 1 h, and the excess crystal violet was washed
with distilled H2O. The stained colonies were converted
into digital images using a scanning device, and the
images were counted using Image J software analysis.
For testing the radiosensitization effect of Zol, PDAC
cells were seeded as described earlier, and Zol was
added in a dose-dependent manner (0, 1, 5, 10, and 20
µM concentrations) and further incubated for 4 h at 37°
C in a humidified atmosphere of 5% CO2 before radiation treatment. The control cells were incubated with
only 10% DMEM. The cells were harvested, fixed,
counted, and the survival fractions at the doses of 0-7
Gy were calculated using the formula described
previously.7

Assay kit (Bio-Rad Laboratories, Hercules, CA, USA). A
total protein from the cell lysates of 40 mg was loaded
into each well of a 10-12% SDS-PAGE, resolved, and
transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore). These membranes were probed with
the following primary antibodies with respective dilutions overnight at 4°C: FDPS (mouse, 1:1000, proteintech # 16129-1-AP), pERK (rabbit, 1:1000, Cell signaling
technology # 9101, Danvers, MA, USA), ERK (mouse,
1:2000, Cell signaling technology # 9102), anti-b-actin
(mouse, 1:5000, Sigma # A1978, St Louis, MO, USA),
and GAPDH. DNA damage/repair antibodies were purchased from Cell signaling technologies. Following
incubation with the appropriate HRP-conjugated secondary antibodies, the membranes were washed in
PBST thrice, and signals were detected with a GE ECL
Plus kit (GE Healthcare Bio-Sciences, Pittsburgh, PA,
USA) and simultaneously exposed to sensitive X-ray
films to detect the signals. For Rac-1 activity measurement, PDAC cells were incubated with increasing doses
of Zol (0-10 mM) for 24 h, and cell lysates were prepared
using lysis buffer containing HEPES buffer (25 mM, pH
7.4), NaCl (150 mM), MgCl2 (10 mM), NP-40 (1%), glycerol (2%). EDTA (1 mM), DTT (1 mM), aprotinin (1 mg/
ml), leupeptin (1 mg/ml), pepstatin (1 mg/ml), PMSF (1
mM), NAF (1 mM), and Na3O4V (1 mM). Zol-treated
and untreated PC cell lysates were incubated with agarose beads coated with GST-bound PAK1 fusion protein
for 1 h. The beads were washed twice with lysis buffer,
and GTP-bound Rac-1 was separated in 10% SDS-PAGE
and immunoblots were probed using anti-Rac1antibody
(23A8, Millipore Sigma). As described previously, we
incubated cell lysates with I mM GDP to serve as a negative control. Rac-1 activity assay was adapted from previous publications.7,8,16,18

Side population analysis

Calcein AM assay

Radioselected and parental PC cells were characterized
for the enrichment of cancer stem cells by side population analysis.16

Similarly, HPNE (3500 cells/well) were incubated with
and without Zol and RT, and cell viability was measured
using Calcein AM compound that fluoresces in live
cells. PDAC cells retention of Calcein AM leads to the
excitement of viable cells. The viable cells with green
fluoresces were measured using the Incucyte" S5 (Sartorius) live-cell analysis instrument.

processed and characterized as described by Boothman
et al.7,17

Clonogenic survival assay

Immunoblot analysis and Rac-1 activity measurement
in PDAC cells
For western blot analysis, PDAC cells were plated at a
density of 1 £ 106 in a 100-mm culture dish and treated
with Zol at respective concentrations for 4 hrs before
radiation exposure. Cells were harvested 24 h post-radiation/Zol treatment in RIPA buffer (50 mM Tris-HCL,
0.1% SDS, 150 mM NaCl, 0.5% sodium deoxycholate
and 1% NP40) containing protease inhibitors (1 mM
phenyl-methyl sulphonyl fluoride, 1 µg/ml aprotinin
and 1 µg/ml leupeptin) and stored at -80°C at least for 4
h. The lysate was thawed and was mechanically disrupted using 25G 7/8 inch syringe needle and centrifuged at 13 000 r.p.m. at 4°C for 30 min. Proteins in the
lysate were quantified using the Bio-Rad DC Protein
4

Xenograft studies
We developed and optimized orthotopic implantation of
tumour cells with a platinum-based fiducial marker coupled with imaging-guided (luciferase and computed
tomography (CT) imaging) RT for treating small animals using SBRT. We utilized a commercially available
platinum-based fiducial marker along with the orthotopic implantation of luciferase-labeled PDAC cells.
Briefly, 6-8-week-old athymic nude male/female (1:1)
mice were injected with 0.25 £ 106 cells and implanted
with the fiducial marker into the head of the pancreas.
www.thelancet.com Vol xx Month xx, 2021
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After tumour cell implantation, the abdominal wall's
fascial layers were closed with catgut sutures, and the
skin incision was closed using wound clips. Seven days
post-implantation, mice were injected (i.p.) with luciferin and imaged using an IVIS machine. Mice were randomized into four groups, each consisting of 5-6 mice.
Group 1 mice were kept as control (no IR treatment),
whereas groups 2 and 3 received fractionated irradiation
doses of approximately 7 Gy once a day for five days or
Zol alone. Group 4 mice received both radiation and
pre-treatment with Zol. The implanted xenografts were
irradiated using a linear accelerator (to deliver SBRT).
To capture acute and chronic effects of Zol, we performed in vivo radiosensitization in two different
batches. The course of treatment and imaging schedules were the same for both batches. The mice group in
batch 1 were euthanized 21 days after treatment initiation, and batch 2 mice were euthanized 4 h after the last
radiation exposure.
The tumour size was monitored and measured once
per week using an IVIS machine.7,16 Finally, 21 days
post-IR, the mice were euthanized, and primary
tumours were resected and divided into two portions.
Part of the tissues was flash-frozen for RNA isolation,
and the remaining part was fixed in 10%-buffered formalin for histopathological analysis. To avoid genderbased biases, we employed an equal number of agematched male and female athymic nude mice (biological variables).

RNA isolation, transcriptome, in silico, and RT-qPCR
analysis in xenograft tissues and clinical specimens
Global transcriptome analysis was performed on total
RNA isolated from xenograft tissues (CD18/HPAF)
treated with and without ZOL and RT. Total RNA was
isolated using Qiagen RNAeasy RNA isolation kit (Qiagen, Valencia, CA, USA) and quantitated using a NanoDrop ND 1000 Spectrophotometer (NanoDrop
Technologies Inc., Wilmington, DE, USA). Based on
the pathological scoring, RNA was isolated from the
PDAC patient’s tissue (specimen obtained through previous clinical trial (NCT01959672)) and blood (through
ongoing clinical trial (NCT03073785)) (RiboPure-Blood
Kit). Samples of 2000 ng total RNA were provided to
the UNMC genome core facility. cDNA libraries were
prepared using the RNA-Seq library kit (Illumina), in
which fragmented RNA is hybridized and ligated to
adaptors to create adaptor-ligated sequences. Following
ligation, the RNA was reverse-transcribed into cDNAs,
purified, and size-selected using Agencourt AMPure XP
beads to generate a size-specific cDNA. Finally, linear
cDNA amplification was performed using limiting cycle
PCR, the cDNA fragments obtained were sequenced
using HiSeq2500, and sequence data were analysed as
reads using the “R” package. Similarly, differentially
downregulated genes identified through RNA-seq in
www.thelancet.com Vol xx Month xx, 2021

xenograft tissues were further validated in total RNA
extracted from xenograft tissues and CD18/HPAF cells
using RT-qPCR analysis (Table S12).

RNA-Seq data analysis
All the raw sequence reads were processed using the
HISAT2-StringTie-Ballgown protocol to retrieve gene
and transcript levels (FPKM). The GRCh38 version of the
human genome and GENCODE v38 version of feature
annotations guided the alignment and read assignment
steps. Differential expression analysis was performed to
yield statistically significant features (p-value < 0.05)
between treatment groups using the Ballgown R package.19 The functional annotation analysis was carried out
using Ingenuity Pathway AnalysisTM and CIBERSORT
analysis.

Patient study design and treatment regimen
This is an open-label, randomized, single-center phase
I/II study. Eligible patients were adults with histologically confirmed PDAC, with either borderline resectable
or unresectable primary tumour, no larger than 10 cm.
Patients were randomized in a 1:1 Ratio to Arm A: stereotactic body radiotherapy (SBRT) with concurrent 5fluorouracil (FU) or capecitabine or Arm B: SBRT with
concurrent 5FU or Cap and Zol. Patients underwent
SBRT (40 Gy to primary, 25-30 to regional lymphatics)
in 5 fractions. Zol (4 mg) was administered through an
intravenous (I.V) route over 15 minutes on the first day
of SBRT. Concurrent chemotherapy was administered
as 5FU 225 mg/m2/day via continuous IV infusion or as
CAP administered orally at 825 mg/m2 twice daily for 4
weeks, starting on day 1 of SBRT. One month after the
combination chemoradiation therapy was completed, all
the patients were evaluated with imaging studies for
resectability. Upon completion of the protocol, all the
patients will be followed every 3 months in the first
year, every 4 months in the second year, and every 6
months thereafter.

Clinical endpoints and assessments
The primary objective was to evaluate the efficacy of
SBRT with concurrent Zol treatment, and the primary
endpoint is planned to evaluate local control. The secondary objectives include toxicity of Zol with SBRT,
local failure-free survival, overall survival, resection rate,
and tumour response. Exploratory objectives include
the identification of biological outcomes and their correlation with treatment regimens of the patients enrolled
in Arms A and B.

Clinical trial sample size calculation
We estimate that there will be about 20 patients
enrolled into each Arm over a 5-year period; the first six
patients in the Arm that patients are receiving Zol
5
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(Zometa) will also be evaluated for the safety of Zol
given concurrently with RT. With conventional SBRT,
about 60% of these patients would be expected to
develop local recurrence by four months of follow-up.
With the radiation therapy and Zol outlined in this protocol, we hope to reduce this rate to 30%. The study
design will follow a two-stage design using a response
endpoint to determine if the regimen is acceptable. The
following monitoring rule will be applied: Optimal twostage design to test the null hypothesis that P<=0.400
versus the alternative that P>=0.700, alpha=0.10, 90%
power. After testing the regimen on 11 patients in the
first stage, the trial will be terminated if 5 or fewer
patients have local control. If the trial goes on to the second stage, a total of 20 patients will be studied. If the
total number of patients with local control is less than
or equal to 10, the regimen is rejected.

Blood and tissue sample collection
We have sequentially collected blood samples from 15
PDAC patients randomized to Arm A (only RT/CAP)
and 11 patients assigned to Arm B (Zol with RT/CAP).
The blood samples collected on day 1 before Zol infusion/RT treatment will be considered a baseline and
compared with Day 5 samples. Based on the pathological score on the tissue samples (0 means no response
and 9 is the complete response), we randomly selected
blood samples from a single patient from both Arm A
and Arm B, and peripheral blood mononuclear cells
(PBMC) were isolated from whole blood and processed
with LSMTM lymphocyte separation medium.20 Total
RNA was extracted from the isolated PBMCs using the
Ambion RibopureTM RNA purification kit (AM1928).
Further, the RNA was processed for transcriptomic
analysis as described in RNA Seq. analysis section.

manufactures protocol (ab133116). The intracellular variation in cholesterol levels was measured by counting
the filipin-positive cells that bind with sterol/cholesterol
using the EVOS" FL auto live imaging system (Life
technologies).

Statistical analysis for in vitro and in vivo studies
An in-house biostatistician performed a detailed statistical analysis. ANOVA was used to compare tumour
weights between groups. The ANOVA assumptions
were assessed using residual plots, and after natural log
transformation, the assumptions appeared to have been
met. A linear mixed model was used to compare photons between groups over time. The model included
fixed effects for the treatment group, day, and group x
day interaction. A random mouse effect was included to
account for correlation within the mouse over time.
Analysis was done on the natural log scale or square
root scale to meet model assumptions (ANOVA). Both
in acute and chronic treatment groups, Tukey’s method
was used to adjust p-values for multiple comparisons at
each level of day and group. For the short-term treatment mice, the photons from the xenograft tumours
were compared using a linear mixed model, as we have
done before. However, we performed statistical analysis
on the square root scale to meet model assumptions.
Student’s t-test was used to calculate the statistical difference between groups in all other in vitro assays. SAS
software version 9.4 was used for data analysis (SAS
Institute Inc., Cary, NC). Graphs were generated using
GraphPad Prism 8 software. Data are presented as
mean§SEM.

Reagents validation
Tumouroid studies
3D pancreatic tumouroids were established from KPC
(25 weeks old) autochthonous mouse models, and
human PDAC tissues and tumouroids' growth and
responses were measured using methods described
previously.16

Cell cycle, apoptosis, ferroptosis, and cell-based
cholesterol assay
Human (CD18/HPAF and T3M4) and mouse syngeneic
(UN-KPC-961) PDAC cells were exposed to Zol (5mM)
for 4 hrs followed by RT (7 GY) treatment for 24 hrs,
and harvested cells were stained with Annexin V/propidium iodide (PI) and analysed using FACS. A similar
Zol+ RT treatment approach was adapted for cell cycle
analysis, as described previously.21 PDAC cells were
pre-treated with Zol (5 µM), exposed to RT (7 Gy of 1
fraction), fixed in 3% paraformaldehyde follwed by
staining with filipin III dye and processed as per
6

Luciferase labeled pancreatic cancer cell lines CD18/
HPAF, T3M4, AsPC-1, BxPC-3 were obtained from Dr.
Ouellette’s Lab. The DNA was isolated, PCR amplified,
and short tandem repeat (STR) profiling was done with
Applied Biosystems. All these pancreatic cancer cells
were routinely inspected for their recognizable morphology in a light microscope, growth curve analysis
using Trypan blue dye, and proliferation assay using tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT). Mycoplasma contamination
was detected by incubating the pancreatic cancer cells
with 4% paraformaldehyde followed by staining with
DAPI solution, and the presence of mycoplasma was
viewed through a fluorescent microscope. Si-RNAs and
CRISPR guide RNAs targeting FDPS were validated
using two independent sequences and clones. All the
antibodies were purchased from well-established vendors and matched for the molecular weight of antibody
of interest with the respective data sheet provided by the
vendors.
www.thelancet.com Vol xx Month xx, 2021
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Results
FDPS and Ki67 co-expression are associated with poor
response to radiotherapy
FDPS expression was demonstrated to be associated
with the progression of various cancers, including
PDAC.7!10 However, its relationship with PDAC RR
and its value as a novel target for PDAC therapy are
unknown (Figure 1a). Through global transcriptomic
data analysis (PAAD), we found that FDPS transcript
levels are significantly higher in pancreatic tumours
than in normal pancreas (Figure 1b). Further, to ascertain if FDPS expression influences response to RT, we
examined the expression of FDPS in surgically resected
PDAC tissues following chemo-radiation treatment
(specimens obtained through our institution's previous
clinical trial (NCT01959672)). The patient’s characteristics and radiation response scores are listed in Tables S1
and S2. The anatomic pathology searched for archived
pancreatic resection specimens from patients that
underwent neoadjuvant chemotherapy. There was no
further enrichment or vetting. Consecutive cases from
that pool that demonstrated tumor regression scores of
1, 2, and 3 and contained sufficient residual paraffinembedded tissue were selected for further study. They
represent a cross-section of patients that met criteria
during that time span.
The patients were categorized as good responders (79), intermediate responders (4-6), and non/poor responders (0-3) based on pathological score. We found
that FDPS was overexpressedand predicted the clinical
outcome between radiation responders versus non-responders. Also, we detected Ki67-positive cells (proliferative marker) to examine the proliferative index in the
serial sections of the same tissues. We found a significant association between high FDPS expression (composite score #4) and poor survival (P = 0.024)
(Figure 1c and d). We also observed that the specimens
with high FDPS expression also showed high Ki67
expression (>4% cells positive) and were significantly
associated with overall poor survival (P = 0.025) of
PDAC patients (Figure S1a and b). We also observed
that PDAC patients who did not respond to RT and
showed the worst survival outcomes had high FDPS
expression. As shown in Figure S1c, we observed a
www.thelancet.com Vol xx Month xx, 2021

Spearman correlation of 0.60 (P = 0.025) between
FDPS and Ki67 co-expression (Table S3). Further, transcriptomic analysis of PDAC samples revealed that
FDPS expression is high in low/non-responders,
whereas responders showed low FDPS levels
(Figure S1d). These results need to be further validated
in a larger PDAC patient cohort.

FDPS expression confers enhanced RR of PDAC cells
We compared cellular radiosensitivity between the
FDPS-high and FDPS-low expressing PDAC cells. To
do this, endogenous expression of FDPS protein in
human and mouse PDAC cell lines and normal immortalized pancreatic cell lines were analysed. FDPS protein
was distinctly higher in several PDAC cell lines tested
than normal HPNE cell lines (Figure 1e) mainly due to
its upstream regulation by EGFR amplification and the
Kras-mediated
AKT/mTOR/SREBP
axis
in
PDAC.16,22,23 Furthermore, radioselected (RS) isogenic
PDAC cells (CD18/HPAF, T3M4) expressing high
FDPS were less sensitive to RT as compared with AsPC1 PDAC cells expressing low FDPS (Figures. 1f and
S2a). Cellular RR in isogenic cell lines was confirmed
by changes in cell morphology, clonogenic survival,
enrichment of side-population and cancer stem cell
markers (ALDH1, CD133, OCT3/4, ESA, and, b-catenin),
pronounced G2/M arrest coupled with the accumulation of cell cycle regulator (cyclin D1 and Cyclin E) along
with enrichment of FDPS, and measurable in vivo
tumour growth with respect to matched parental cells
(Figures. 1f and g; S2a!e). These results confirm and
validate the effect of RS in the isogenic sublines generated through fractionated radiation relative to non-radiated parental PDAC cells.

Genetic and pharmacological suppression of FDPS
increases the radiosensitivity of PDAC cells
To analyse the impact of FDPS expression on PDAC cell
radiosensitivity, we suppressed FDPS expression in
CD18/HPAF and T3M4 PDAC cell lines using the
CRISPR/Cas9 system. Cells transduced with FDPS-specific sgRNA (via with CRISPR/Cas9) were isolated
through FACS analysis (GFP positive), and FDPS
knockdown (KD) cells showed a difference in morphology as compared with parental control PDAC cells
matched for passage (Figure S3a!c). In both the PDAC
cell lines, we observed a decrease in FDPS protein upon
KD (Figure 1h), which was linked to increased PDAC
cell radiosensitivity (Figures. 1i; S3d). Reduced FDPS
expression was also accompanied by decreased phosphorylation of AKT and ERK, but no change in their
respective total proteins (Figure S3e). Based on previous
reports demonstrating Zol can target FDPS,7,8,10,24 we
wondered that whether Zol can radiosensitize PDAC
cells. We found that pre-exposure of human PDAC cells
to Zol at 1, and 5 µM could decrease PDAC cells survival
7
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Figure 1. FDPS is overexpressed in pancreatic cancer and predicts the response of PDAC patients and cells to RT. (a) Cartoon representing the major impact of radiation on primary PDAC cells and its association with FDPS expression in radioresponder and nonresponder PDAC patients. (b) Box plot illustrates FDPS expression (P = 8.4e!08, student’s t-test) in TCGA-PDAC (n = 170) and GTEx
normal pancreas (n= 167) (Courtesy: GEPIA webserver). (c) Kaplan-Meier survival curves illustrate the overall survival difference
between PDAC patients on the basis of the FDPS composite score. FDPS (n = 14, P = 0.024, log-rank test)-positive or high-expressing
patients had statistically signiﬁcant lower survival than negative or low-expressing patients. Tick marks on the graph indicate censored subjects. (d) Representative images show histology and FDPS-positive expression in serial sections of radioresponder and
non-responder PDAC tissues. (e) Western blot analysis of FDPS protein expression in normal immortalized pancreatic (HPNE), human
PDAC, and mouse syngeneic PDAC cells. (f) Clonogenic survival assay illustrating relative RR of CD18/HPAF vs. CD18/HPAF RS

8

www.thelancet.com Vol xx Month xx, 2021

Articles

without causing a cytocidal effect. Higher concentrations of 10 and 20 µM caused cytotoxicity, as evidenced
by reduced or no colonies (Figure 2a and b). We also
observed a similar significant radiosensitization effect
of Zol in murine syngeneic PDAC cells (UN-KPC-961)
(Figure S4a and b). In contrast, dose-dependent treatment of normal immortalized human pancreatic ductal
epithelial cells (HPDE) with Zol did not affect the survival of colonies at lower concentrations (1 and 5 µM).
However, Zol exhibited significantly cytotoxic effects at
higher (10 and 20 µM) concentrations (Figure 2c and
d). Similarly, hTERT immortalized human pancreatic
nestin-positive cells (HPNE) also showed radiosensitivity only with higher concentrations of Zol (5 µM) but
not with Zol alone exposure or a lower concentration
(1 µM) (Figure S5a and b). We used a cell-based cholesterol assay to predict the FDPS inhibitory activity of Zol.
Treatment with either Zol alone or with RT reduced
intracellular cholesterol levels compared to control and
radiation-treated PDAC cells (Figure S6a and b). Overall, these results indicate that targeting FDPS by Zol
could radiosensitize PDAC cells but will exhibit radiosensitizing effects only at higher concentrations and
would not affect FDPS activity as a single agent in normal pancreatic cells. Hence, targeting FDPS using Zol
will sensitize pancreatic tumours effectively without
causing side effects to normal uninvolved pancreatic
cells.

Zol enhances radiosensitivity by abrogating radiationinduced G2/M arrest accompanied by induction of
apoptosis
We speculated that Zol treatment enhances radioresponse by manipulating the cell cycle and apoptosis in
PDAC cells.25 We found that radiation alone induced
G2/M arrest and Zol alone enhanced S phase arrest.
However, when both human and murine PDAC cells
were pre-treated with Zol followed by radiotherapy, they
decreased G2/M and S phase arrest. These data suggest
that Zol abrogates RT-induced G2/M arrest
(Figures. 2e, f; S7a!c). Furthermore, the cell cycle
changes upon Zol and RT treatment were reflected in
decreased cyclin D1 and cyclin B1 protein expression in
both human and mouse PDAC cells (Figures. 2G; S7d).
Complementing this data, pre-treatment of human and

mouse PDAC cells with Zol for 4 hrs followed by RT
resulted in a significant increase in apoptosis compared
to Zol or RT alone (Figures. 2h, i; S4c and d). Furthermore, compared with single treatments, the combination treatment also increased lipid peroxidation, the
build-up of which facilitates a form of programmed cell
death known as ferroptosis26 (Figure 2j and k). These
data demonstrate that Zol radiosensitizes PDAC cells,
in part, by affecting G2/M arrest and inducing apoptosis
via FDPS inhibition.

Zol enhances radioresponse by suppressing PDAC
xenograft growth and metastasis
We utilized the mouse pancreatic orthotopic tumour
model to identify the molecular mechanism(s) of Zolmediated radiosensitization in vivo. First, we performed
a biodistribution study using radiolabeled Zol (3H-Zol)
in non-tumour-bearing mice to evaluate whether Zol
reaches the pancreas. Comparative biodistribution of a
radiolabeled probe into different organs with time kinetics shows that Zol accumulated in the pancreas 4 hrs
after tail vein injection and remained in pancreas for up
to 120 h (Figure S8a). Next, we implanted CD18/HPAF
cells in the mouse pancreas and a platinum-based fiducial marker to precisely locate the xenograft tumour
using CT to better improvise the treatment planning
(Figure 3a and b). We found that CD18/HPAF xenografts treated with RT and i.p injected Zol (16.4 µg/
mouse, mouse equivalent dose calculated based on previous clinical trials) exhibited significantly greater RT
response and reduced xenograft tumour weight and
metastasis as compared to Zol or RT alone and control
groups (Figures. 3c!e and S8b). A linear mixed model
analysed the photons measured using IVIS imaging at
days 0, 7, and 21. There was a significant interaction
between the treatment group and days, indicating the
treatment effect differed by day (P = 0.0064) (Tables
S4, S5, and S6). The overall pairwise comparison
between treatments groups is significant at Day 21 (Rad
vs. Zol+Rad (P = 0.0126), Zol vs. Zol+Rad (P = 0.0224))
(Table S6). Xenograft tumour weights in the four
groups were found to be significantly different based on
ANOVA. Pairwise comparison between Zol and Zol
+Rad treated xenograft tumour weight was significant
(P = 0.0028) (Tables S7 and S8). Pancreatic tumour

(P = 0.01 (2.5 Gy), P = 0.0006 (5 Gy), P = 0.009 (7 Gy), n=3) and T3M4 vs. T3M4 RS (P = 0.01 (2.5 Gy), P = 0.03 (5 Gy), P = 0.0007 (7 Gy))
and AsPC-1 vs. AsPC-1 RS (P = 0.001 (2.5 Gy), P = 0.0004 (5 Gy), P = 0.006 (7 Gy), n=3) PDAC cells. The survival curves were generated
by calculating the plating efﬁciency and survival fractions of colonies obtained using different plating densities of parental and isogenic PDAC cells. (g) Persistent exposure of PDAC cells to radiation results in increased expression of proteins involved in cell cycle
(cyclin D1 and Cyclin E) and enrichment of pancreatic cancer stem cells markers (ALDH1, CD133, OCT3/4, ESA, and b-catenin) and
FDPS in RS cells as compared to parental cells. (h) Western blot analyses show a reduction in FDPS protein in the CRISPR/Cas9selected stable clones compared to passage-matched control cells. Beta actin was used as an internal loading control. (i) Clonogenic
survival assay showed that CRISPR/Cas9-mediated FDPS KD reduced the survival fraction of PDAC cells. CRISPR KD Clone 2 (CD18/
HPAF) and Clone 1 (T3M4) cells exhibited enhanced sensitivity to RT relative to the parental control [CD18/HPAF (con vs Cl#1
(P = 0.025 (5 Gy), con vs Cl#2 P = 0.002 (3 Gy), P = 0.0001 (5 Gy)), (n=6), T3M4 (con vs Cl#1, P = 0.03 (5 Gy), con vs Cl#2, P = 0.04 (5
Gy)), n=3]. Statistical analysis was done by student’s t-test.
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Figure 2. Zol treatment enhances PDAC cell radiosensitivity by affecting the cell cycle and inducing apoptosis. (a and b) Clonogenic
survival assays were performed on PDAC cells treated with increasing concentrations (0-40 µM) of Zol followed by RT (7 Gy). (a) The
bar graph shows decreased colony numbers as a result of dose-dependent treatment of Zol [CD18/HPAF (con vs Zol (5 µM)
(P = 0.03), con vs Zol (10 µM) (P = 0.0006), con vs Zol (20 µM) (P = 0.0004), Rad vs Zol (5 µM)+ Rad (P = 0.003), Rad vs Zol (10 µM)+
Rad (P = 0.001), Rad vs Zol (20 µM)+ Rad (P = 0.001)), T3M4 (con vs Zol (5 µM) (P = 0.04), con vs Zol (10 µM) (P = 0.007), con vs Zol (20
µM) (P = 0.003), Rad vs Zol (5 µM)+ Rad (P = 0.001), Rad vs Zol (10 µM)+ Rad (P = 0.002), Rad vs Zol (20 µM)+ Rad (P = 0.003)), n=3].
(b) Representative images of surviving colonies after Zol and RT treatments. (c and d) Effect of Zol on radiosensitization of normal
immortalized pancreatic cells. Normal immortalized HPDE were subjected to various doses of Zol. (c) The bar graph depicts the
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xenografts and major vital organs (liver and spleen)
were subjected to histological analysis to examine
tumour necrosis and acute or chronic toxicity
(Figure S8c and d). Zol and RT alone modestly reduced
the survival of PDAC cells with increased necrosis in
the RT alone group. There was no sign of drug- or RTrelated toxicities in the liver and spleen in any of the
treatment groups. These observations were further validated by evaluating the expression of Ki67 (proliferative
marker) and cleaved caspase 3 (apoptosis marker) in
xenograft tissues. Our IHC staining for Ki67 and
cleaved caspase 3 antibody revealed that Zol alone and
in combination with radiation-exposed xenograft tissues
showed significantly decreased Ki67 nuclear staining
and increased positive cytoplasmic expression of cleaved
caspase-3 as compared with control and radiation alone
treated xenografts (Figure S9a!d). These results are the
consequence and the signs of necrosis and the histopathological difference between treatment groups, as
observed in Figure S8c and d).

Zol treatment radiosensitizes 3D murine and human
PDAC tumouroids
To determine the radiosensitization efficacy of Zol in 3D
in vitro models of PDAC, we utilized recently developed
murine KPC and human PDAC tumouroid models. We
found that pre-treatment of tumouroids with Zol followed
by RT significantly reduced growth of mouse (P = 0.03,
P = 0.01) and human (P <0.01, P <0.05) tumouroids at
days 3 and 5 post-IR+ Zol treatments (Figure 3f!j). Thus,
our results in tumouroid and xenograft models suggested
that Zol radiosensitizes both human and mouse PDAC.

Transcriptomic analysis reveals Zol combined with RT
induces DNA damage and repair gene signature
through Rac1
DNA damage and radioresponse signals are short-lived.
Therefore, to assess the effects of Zol post-radiation, we

used a short-term in vivo treatment model. As expected,
Zol treatment of irradiated xenograft tumours significantly reduced tumour size and decreased xenograft
growth (Rad vs. Zol (P = 0.0161), Zol vs. Zol+Rad
(P = 0.0029), Tables S9, S10, and S11), as evidenced by
the decrease in photons in the IVIS images on day 7 relative to Zol and RT alone at Day 0 (randomization)
(Figure S10a, b, Tables S9, S10, and S11). We excised
xenograft tissues immediately after the last radiation
and performed global transcriptome analysis on total
RNA isolated from short-term-treated xenograft tissues
(CD18/HPAF) exposed to Zol and/or RT. All sequenced
and mapped genes were screened between untreated
control and treated (Zol/RT alone and in combination)
cells. A total of 5942 common and 353 differentially
expressed genes (DEGs) (above and below the log2fold
change of 2, P <0.05, FDR <0.01) were observed
between groups (Figure 4a). Among the DEGs,
TM4SF4, UNC5B, PDK4, ID1 (related to mevalonate
pathway), UBAP2, PLK2, LPCAT1, LAMA3, FSCN1, and
BHLHE40 were differentially (top 5 DEGs in bold) regulated in response to Zol-mediated radiosensitization in
PDAC cells (Figure S10c). Our gene enrichment and
pathway analysis through KEGG revealed that several
critical pathways such as (a) Zoledronate action pathway, (b) Rho GTPases, (c) Ras, (d) RAF/MAP kinases,
(e) DNA double-strand break, (f) PI3K-AKT, (g) G2/M
transition, (h) DNA damage response, (i) ATM and (j)
ATR signalling pathways were significantly enriched in
cells treated with Zol and RT (Figure 4b). Interactome
analysis revealed a significant association of Rac1 with
Zol activity, which was previously shown to be associated with RR in PDAC (Figure 4c).27!29
We exposed PDAC cells to various Zol concentrations (0, 1, 5, and 10 µM) and performed a Rac1 pulldown assay to assess its dose-dependent inhibition of
Rac1 activity. Exposure of PDAC cells to Zol reduced
GTP-bound Rac1 (Figure 4d). Lysate pulldown with
GDP (guanosine50 -diphosphate) served as a negative
control. Similarly, Zol treatment alone increased the

average number of colonies that survived after Zol treatment, and colony numbers were quantiﬁed using Image J software (Con vs.
Zol (10 µM) (P = 0.02, Con vs. Zol (20 µM) (P = 0.01), n=3). (d) Representative HPDE colonies stained with 0.5% crystal violet in 25%
methanol. (e) Bar graphs show the percentage of cells (CD18/HPAF) in each cell cycle phase after Zol and/or RT treatment. (f) Histogram showing percentage of cells distributed in each cell cycle phase in response to Zol and/or RT treatment in PDAC cells. (g) Western blot analysis conﬁrms cyclin D1 and cyclin B1 protein levels following Zol and RT treatment in PDAC cells. (h and i) Exposure of
PDAC cells to Zol and RT results in apoptosis induction. (h) The bar graph depicts the percentage of early and late apoptosis as
detected by Annexin V and propidium iodide (PI) staining (Zol vs. Zol (5 µM) + Rad (P = 0.028, early apoptosis), Rad vs. Zol (5 µM)
+Rad (P = 0.026, early apoptosis), Rad vs. Zol (5 µM)+Rad (P = 0.0008, late apoptosis), n=4). (i) Representative annexin V/PI staining
shows post-treatment effects of Zol+RT. Scatter plots depict the density of live (lower-left), early (lower-right), late or necrosis
(upper-right), and only necrotic cells (upper-left) in each quadrant. (j and k) Pre-treatment of PDAC cells with Zol followed by RT
increased lipid peroxidation. Notably, a form of cell death known as ferroptosis is induced by the lethal build-up of peroxidated lipids. PDAC cells were pre-treated with 5 µM of Zol 4 h before a single fraction of 3 Gy radiation. Cells were ﬁxed 12 h after RT, and
lipid peroxidation was assessed via C11 BODIPY staining. C11 BODIPY causes the peroxidation of lipids to stain green while non-peroxidated lipids stain red. A ratio of these two colours produces a relative oxidative state of the lipid species between treatment
groups. (j) The bar graph demonstrates the increase in mean ﬂuorescence intensity of peroxidated lipids due to Zol+RT treatment
compared to Zol or RT alone and untreated control cells [CD18/HPAF (Rad vs Zol+Rad (P = 0.03)), T3M4 (Zol vs Zol+Rad (P = 0.002),
Rad vs Zol+Rad (P = 0.03)), n=3]. (k) Representative confocal images demonstrate the variation in normal lipids (Red) and peroxidized lipids (Green). Statistical analysis was done by student’s t-test.
www.thelancet.com Vol xx Month xx, 2021
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Figure 3. Radiosensitization efﬁcacy of Zol in PDAC xenograft, in vitro 3D murine KPC tumouroids, and human PDAC tumouroid
models. (a) Representative MRI imaging showing implantation of ﬁducial marker along with xenograft PDAC cells in athymic nude
mice. (b) Schema showing treatment schedule of Zol and RT. (c and d) Mice were (i.p.) injected with luciferin and imaged using an
IVIS at 0, 7, and 21 days of Zol and RT treatments. (c) Dot plot showing tumour volume/response measurement as total photon ﬂux
at 21 days post-treatment in each group (Zol vs. Zol+Rad (P = 0.0224), Rad vs. Zol+Rad (P = 0.0126), n=6, ANOVA, Tukey’s multiple
comparison test). (d) Representative images show bioluminescent images of mice in all groups. (e) The bar graph shows the quantiﬁcation of xenograft tumour weights in grams (Zol vs. Zol+Rad (P = 0.0028), n=6, ANOVA, Tukey’s multiple comparison test). (f) The
bar graph shows the mean growth of KPC tumouroids exposed to no drug, Zol, and/or RT alone. Tumouroid growth (µM) was measured using software associated with Zeiss Live imaging system. Tumouroid size at day 3 (Rad vs Zol+Rad (P = 0.03)), Student’s ttest) and day 5 (Rad vs Zol+Rad (P = 0.01)), n = 6, student’s t-test) was normalized to day 0. (g) Representative light microscope
images of KPC tumouroids were taken at days 0, 3, and 5 following drug treatment. (h) Histological examination revealed more viable tumour cells in control (no drug treatment) tumouroids compared with tumouroids treated with RT and Zol alone and in
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un-prenylated form of both Rac1 and CDC42 compared
to untreated control PDAC cells (Figure 4e). Interestingly, we also tested whether the ectopic expression of
constitutively active Rac1 (Rac1G12V mutant) in PDAC
cells could reverse the in vitro Zol radiosensitizing
effects. Despite constitutive active Rac1, pre-treatment
with Zol alone and in combination with RT showed consistent significant radiosensitizing impact similar to
observations in other human and mouse PDAC cells
(Figure S11a and b), indicating that Zol exhibits global
disruption of Rac1 activity irrespective of its mutant status. In addition, Zol treatment in combination with RT
resulted in synergistic control and an increase in the
un-prenylated forms of Rac1, CDC42, and Rho G, which
correlated directly with relative FDPS inhibition in
PDAC cells human and mouse PDAC (CD18/HPAF,
T3M3, and UN-KPC-961) cells (Figure 4f). This suggests that Zol-mediated FDPS inhibition regulates prenylation of small GTPases, which could be a
mechanism controlling the DNA damage signals that
emerge immediately after RT. We also observed that
DNA damage-response MRN (MRE11-RAD50-NBS1)
complex and DNA repair-associated tumour suppressor
protein pBRCA1 were reduced upon Zol and RT in
PDAC cells (Figs. 4f and S10d) with no changes in
Ku80 double-stranded DNA break repair protein, indicating that inhibition of these DNA repair pathways is
the reflection of sustained radiosensitization effects of
Zol (Figure 4f). Notably, IHC analysis for DNA damage
response proteins (RAD50 and pP95 (NBS1)) in xenograft tissues indicated significantly decreased expression for analysed proteins (RAD50 (P < 0.001) and
pP95 (P < 0.001) in the Zol+RT treatment group relative to radiation alone confirming the retention of combination effect in vivo (Figure S12a-d). In addition,
several genes related to Rho and Rac1 signalling were
downregulated in response to Zol+RT relative to RT
alone (Figure S13a and b). Further, transcriptomic analysis on xenograft tissues treated with Zol and RT demonstrated downregulation of genes significantly
associated with the Rho family of GTPases. Among Rho
subfamily genes, Rac1 and Rac2 are significantly downregulated compared to other genes of the same subfamily (Figure S14). In addition, depletion of FDPS in
PDAC cells reduced the mean number of survival colonies by downregulating Rad50 protein levels, indicating
Rad50 is a direct target of FDPS (Figure 4g and h).
Overall, inhibition of FDPS by Zol reduces protein prenylation and small GTPase activity; thereby, it further
impairs DNA damage, response, and repair signalling
resulting in enhanced radiosensitivity of PDAC cells in
both in vitro and in vivo (Figure 4i).

Evaluating the safety and efﬁcacy of Zol combined
with SBRT/5FU or capecitabine in the clinical trial
In our ongoing Phase I/II clinical trial evaluating the
safety and efficacy of ZOL in radiosensitizing PDAC
tumours
in
borderline
resectable
patients
(NCT03073785), PDAC patients were randomized to
either ARM A (RT/5FU or capecitabine) or ARM B (RT/
5FU or capecitabine + Zol). Patient randomization,
intervention, and follow-up are demonstrated in
Figure S15. The trial has passed first (safety) and second
(first stage of the two-stage design) interim analyses and
has entered the second stage. To date, 45% (5/11) of
patients who received Zol+RT and 33% (5/15) who did
not receive Zol (RT alone) became surgical candidates
and underwent surgical resection. One patient in the
Zol arm had a complete pathologic response.

Zol enhances the radioresponse of human PDAC
tumours by exerting systemic immunomodulatory
effects
Next, we focused on the correlation of Zol treatment
with immunomodulatory effects. Hence, we performed
CIBERSORT analysis on the transcriptomic data
obtained through Human PBMCs and xenograft tissues
(Figure 5a). First, the surgically resected PDAC tissues
were pathologically evaluated for their clinical response
to Zol+RT treatment. Based on the pathological score (0
means no response and 9 is the complete response), we
selected blood samples and extracted blood samples
from a single patient from Arm A and B. Then, we
determined the gene expression levels of immune
response and the tumour microenvironment (TME) factors. As expected, PDAC patients in Arm B treated with
Zol+RT had significantly higher putative fractions
(CIBERSORT) of activated NK cells, activated dendritic
cells, CD4+ T memory resting, CD4+ T cell naÿve, and
plasma cells relative to Arm A patient treated with RT
alone, but there was no difference in the proportion of
naÿve B cells (Figure 5b). Specifically, we found significantly higher proportions of plasma cells (N=4) and differences in monocytes (N=4) and activated NK cells
(N=4) on day 5 as compared with day 1 of Arm B
patients (Figure 5c-e). We also found that the proportion
of variants of gd T cells are expanded upon Zol treatment in PDAC patients’ peripheral blood. Among the
subpopulation of gd T cells (d1, d2, d3) Vg9Vd2 is predominantly (90%) present in peripheral blood.30
Hence, we analysed the proportion of T cell receptor
(TCR) g and d repertoire in the RNA seq data obtained
from Day1 and Day 5 of RT+Zol treatment. We found
that several variants and expansions of TCR g and d

combination. (i) Bar graph showing average growth/response of human PDAC tumouroids after drug treatment. Tumouroid size at
Day 5 (Rad vs Zol (10 µM) (P = 0.0322), Rad vs Zol (20 µM) (P = 0.0093), Rad vs Zol (20 µM) + Rad (P = 0.0159), n=6, student’s t-test)
were normalized to Day 0 of respective tumouroids. (j) Representative images depict the response of human PDAC patient-derived
tumouroids to various doses of Zol alone and in combination with RT.
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Figure 4. Zol and RT treatment modulate DNA damage response by deactivating Rho small GTPases, thereby reducing DNA doublestranded break repair proteins. (a) Venn diagram showing speciﬁc differentially expressed genes in different treatment groups. (b)
Pathway enrichment analysis of common and unique genes in the RT versus Zol+RT group. (c) Integrated network analysis of differentially expressed genes in the Zol+RT versus RT group using STRING version 10.5. (d) Dose-dependent treatment of PDAC cells
with Zol decreased Rac-1 activity. (e) Western blot analysis conﬁrmed the expression of prenylated (Arrows in red) and unprenylated
(Arrows in green) forms of Ras family members Rac-1 and CDC42 upon dose-dependent treatment of Zol in BxPC3, T3M4 and CD18/
HPAF PDAC cells. (f) Human and mouse PDAC cells were exposed to Zol (5 µM) 4 h prior to RT, lysates were prepared, and proteins
were separated using SDS-PAGE and analysed for antibodies speciﬁc for small GTPases (Rac-1, CDC42, and Rho G) and DNA repair
and damage signalling (RAD50, MRE11, pBRCA1, and KU80) (g and h) Transient knockdown (KD) of FDPS in PDAC cells suppressed
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repertoire were high on Day 5 compared to Day 1 of the
same patient (Figure 5f). This is mainly due to the accumulation of isopentenyl pyrophosphate (IPP) as a result
of FDPS inhibition by Zol in the tumour cells resulting
in stimulation and activation of gdT cells (Vg9Vd2).
Further, we validated these immune cell signatures
in the RNA sequence analysis from xenograft tissues by
genes mapping aligned for mouse sequence and processed with CIBERSORT and Kallisto analysis. As shown
in the heatmap, the proportions of genes associated
with Macrophage M0 are decreased, whereas putative
fractions representing M1 Macrophages and NK cells
resting are increased in Zol+RT treated mice compared
with radiation alone treated xenografts (Figure 5g).
Additionally, the fibroblast activation-associated gene
signatures were downregulated in Zol and RT-treated
xenograft tumours (Figure 5h). These downregulated
TME-associated gene signatures were further validated
by RT-qPCR analysis in the PDAC cells and xenograft
tissues treated with and without Zol and RT
(Figure S10e). Our RT-qPCR results confirmed a significant downregulation of TGFb3, FGF2, MIF, PDGFRb,
and IL6 in Zol+RT treated xenograft tissues relative to
RT alone treatment. Finally, PDAC cells exposed to Zol
+RT also showed significant downregulation of IL6
compared to isogenic cells treated with radiation alone.
These data suggest that Zol treatment have a significant
impact on immune cell activation and negative regulation of immunosuppressive cells. Thus, Zol may be beneficial in enhancing the efficacy of immunotherapy in
the treatment of PDAC. Altogether, these preclinical
and clinical data suggest that the therapeutic effect of
Zol on PDAC cells involves inhibition of PDAC growth
(Figure 6).

Discussion
RT effect is minimal in PDAC patients due to intrinsic
and acquired resistance 5. This study sought to identify
and characterize pathways contributing to RR in PDAC
that can be explored as novel targets for radiosensitization. Recent studies have highlighted FDPS as a critical
determinant of cancer progression and survival in acute
myeloid leukemia, melanoma, sarcoma, and PDAC
patients.7,31 In addition, FDPS is a critical gene involved
in CBS and is required for the isoprenylation of Rho
GTPase Rac1, which drives K-Ras-driven cancers.2932!34
Unbiased pathway analysis indicated that FDPS to be
differentially expressed and associated with the RR phenotype 7, but the mechanism by which FDPS regulates

response to radiation and the therapeutic potential of
targeting FDPS to overcome RR was not been explored.
In this study, we investigated the role of FDPS in
PDAC RR. This was clinically supported by the
increased expression of FDPS along with Ki67 in the tissue of PDAC patients treated with neoadjuvant hypofractionated stereotactic RT. Furthermore, we
demonstrated that significantly higher expressions of
FDPS and Ki67 were associated with RT refractoriness
and with poor survival. This was similar to the observation of Kim et al. 10, who demonstrated that FDPS was
highly expressed in aggressive glioma and associated
with poor survival. Our transcriptomic analysis of
PDAC tissues is the first report of FDPS as a biomarker
for RT response. Furthermore, through in silico analysis,
we show that PDAC patients have significant overexpression of FDPS compared to the normal pancreas.
FDPS deregulation has also been reported in glioblastoma, colon, and prostate cancer progression.8!11 When
a cancer cell is irradiated, the stress response signal activates the sterol regulatory element‑binding protein
(SREBP). When SREBP enters the nucleus, it binds to
the sterol response element present in the FDPS promoter 35. This research points towards the likelihood
that sustained SREBP mediates FDPS overexpression
in response to the radiation treatment.36 Our data show
that chronic RT of PDAC cells results in upregulation of
FDPS, cyclin D1, cyclin B1, and cancer stem cell
markers in PDAC cells accompanied by altered cellular
morphology, increased survival facilitated by G2/M
arrest, and an increased side population.
Furthermore, depletion of FDPS led to greater sensitivity to RT than control cells with a marked reduction
in phosphorylated AKT, ERK, and DNA repair protein,
RAD50. This is in agreement with our previous work
and others, showing that FDPS modulates phosphorylation of AKT and ERK.8!11 These data also provided a
rationale to target FDPS and prompted us to test the
utility of Zol, a specific inhibitor of FDPS,37,38 as a radiosensitizer for PDAC. Indeed, Zol administration before
RT has been shown to prevent mesenchymal stem cell
loss.39 Furthermore, treatment with Zol in conjunction
with RT resulted in reduced colony growth, enhanced
apoptosis, and retracted radiation-associated G2/M cell
cycle arrest. Zol demonstrated similar anticancer effects
in osteosarcoma, esophageal, and breast cancers related
to skeletal or bone metastasis with a low radiation
dose.40!42
Our orthotopic model is the first in vivo approach to
mimic clinical radiosensitization, which differs from

FDPS and subsequently reduced RAD50. (g) Clonogenic survival assay conﬁrmed that FDPS suppression reduced the number of colonies as quantiﬁed using Image J software. The bar graph represents the results of the mean §SE of colonies that survived after
FDPS KD and RT (SCR vs. SCR+RT (P = 0.034), Si-A vs. Si-A+RT (P < 0.001), Si-B vs. Si-B+RT (P = 0.036), SCR+RT vs. Si-A+RT (P = 0.0072),
Si-A+RT vs. Si-B+RT (P = 0.049), SCR+RT vs. Si-B+RT (P = 0.0048), n=3, student’s t-test). (h) FDPS transient transfection potency was
veriﬁed using lysates prepared from transfection of non-targeting (Scramble) and siRNA targeting FDPS in PDAC cells and analysed
for FDPS, RAD50, and b-actin protein by western blot analysis.
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Figure 5. Pre-treatment with Zol induces immunomodulatory effects in conjunction with neoadjuvant RT and capecitabine in borderline resectable PDAC patients. (a) Cartoon demonstrating the systemic and local immunomodulatory effects of Zol identiﬁed
from the PDAC patientPBMCs and xenograft tissues. (b) Heatmap representing immune fractions between Day 1 and Day 5 of
patients in Arm A and Arm B. Scale- fold change fractions of immune cell types in peripheral blood. (c-e) Box plot showing an
enhanced response of immune components (plasma cells (P = 0.041), monocytes (P = 0.089), and activated NK cells (P = 0.23), Pairwise t-test) in Arm B patients treated with RT+ZOL at Day 5 (n=4) relative to Day 1 (n=4). (f) Stacked bar plot showing the expansion
and proportion of TCRg and TCRd repertoire in PBMCs isolated from RT alone and RT+Zol treated PDAC patients enrolled in ongoing
Phase I/II clinical trial. (g) Heatmap of tumour microenvironment-related gene sets signiﬁcantly impacted upon Zol and RT treatment
versus RT alone in xenograft model tissues with P <0.05 and FDR <25%. (h) Heatmap of signiﬁcantly downregulated genes related
to cancer-associated ﬁbroblast when comparing Zol+RT treated xenograft tumours versus RT alone.
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most conventional superficial xenograft models.43,44
This clinically relevant model allowed us to deliver
higher doses of RT to tumours while minimizing the
chance of RT exposure and radiation-induced toxicity to
uninvolved vital organs located closer to the pancreas,
such as the liver, intestine, and kidney.45 The in vivo
radiosensitization studies showed that xenograft
tumours treated with RT and i.p. injected with Zol (16.4
µg/mouse, mouse equivalent to clinical dose) 46 had a
significantly greater response, higher tumour shrinkage, and lower metastasis incidence as compared to Zol
or RT alone and control groups. Furthermore, upon histological analysis of vital organs such as the spleen and
liver located close to the pancreas, no signs of drug or
radiation-related acute and chronic toxicities were
observed.
Similar to in vivo radiosensitization with Zol, we also
observed significant retardation of KPC and human
PDAC patient-derived tumouroids growth with Zol+RT
exposure. These findings in the 3D models will useful
in accurately predicting the pharmacological impact of
Zol on the heterogeneous human pancreatic tumour
microenvironment, which is a major challenge in
PDAC.47
Through our global transcriptomic analysis followed
by in silico analysis on the pancreatic xenograft tissues,
we were able to identify modulation of PI3K, Ras, Rho,
and DNA damage response signalling as mediators of
Zol-induced radiosensitization. Further, an interactome
analysis of the top differentially expressed genes in radiation- and Zol-treated groups revealed Rac1 as one of
the mediators of the FDPS effect. Previously, Rac1 was
shown to be overexpressed and constitutively activated,
and its activity was unaffected by anticancer
agents.28,29,33,34. However, we found that Rac1, associated with PDAC RR, was downregulated and among the
network genes affected with Zol+Rad treatment. Moreover, inhibition of prenylation of Rac1 and CDC42 small
GTPases, along with the decreased accumulation of
intracellular cholesterol, served as useful readouts of
the efficiency of Zol in inhibiting FDPS activity. In fact,
inhibition of prenylation is effective against Ras-driven
and Rac1-hyperactivated tumours.34 In addition, Zol
treatment suppressed Rac-1 activity in a dose-dependent
manner. Thus, both genetic and pharmacological inhibition of FDPS enhanced radiosensitivity by impairing
DNA damage response genes such as ATM, pP95, and
Rad50 through upstream Rac1 activation. These studies
are substantially supported by the work of Varela et al.,
which demonstrated that direct inhibition of ATM signalling by Zol and prevented DNA damage signalling.48
Through our study, we elucidated the direct link
between FDPS-Rac1-ATM signalling as a possible mechanism of RR.
Supportively, Zol is also under investigation as a
combination agent with tyrosine kinase inhibitors in
non-small cell lung cancer (NSCLC) (NCT03958565), as
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a surgical adjuvant in giant cell cancer of bone
(NCT03295981), and in a study that is evaluating safety
and tolerability of Zol before and after surgery in
patients
with
grade
I-III
chondrosarcoma
(NCT03173976). Our interim results show that concurrent Zol and SBRT is a safe and feasible approach in
this cohort. The resection rate after neoadjuvant therapy
was 40% and 33% with and without Zol, respectively. In
addition to its direct anti-tumour effects, Zol has been
shown to influence macrophage polarization, gd T cell
expansion, enhancement of natural killer (NK) cell activity, Tregs activation and infiltration, modulation of PDL1 expression, and T helper and cytotoxic cell functions.12,49 In addition, Zol treatment also expansion of
human Vg9/Vd2 T cells and TCR-dependent phosphorylated metabolites to cytolyze cancer cells by secreting
chemokines and cytokines. Activated gd T exert cytolytic
effects against tumour cells or APCs in an MHC-independent manner.30 In a recent study, Merli et al. demonstrated that Zol infusion after administration of
TCRab/CD19 depleted cells enriched with the mature
natural killer and TCRgd T cells isolated from haploidentical hematopoietic stem cell transplantation
(HSCT) donor (haplo-HSCT) accelerated TCRgd T cells
differentiation and expansion. By this approach, it has
been shown that Zol infusion after transplantation promoted immune reconstitution and reduced disease
recurrence and risk of post-infection-related complications in pediatric acute leukemia patients.50 Several
clinical studies such as Austrian Breast and Colorectal
Cancer Study Group trial 12 (ABCSG-12), ZometaFemara Adjuvant Synergy Trial (ZO-FAST), and Adjuvant Zoledronic acid to reduce recurrence
(AZURE) studies demonstrated modulation of
immune-suppressing regulatory T (Treg) cells by inhibiting its proliferative capacity via downregulating CCR4,
PD-1, CTLA-4 and cells the immunomodulatory effects
of Zol by receptor activator of nuclear factor kappa-B
ligand (RANKL) on Treg cells.51 Furthermore, a seminal
study by Weber and colleagues demonstrated that Zol
alone and in combination with surgical trauma significantly increased infiltration and shifted systemic macrophage polarization toward M1 type in spleen, lung, and
skin of Wister rat model.52 All these studies provide
additional evidence of Zol contributing towards modulation of the immune system. PDAC is very difficult to
treat and resistant to most conventional therapies due to
dense stromal meshwork and immunosuppressive
microenvironment.53 To study Zols immunosuppressive and immunomodulatory effects, we performed
CYBERSORT analysis on the RNA-seq data obtained
from PDAC patient-derived PBMCs and xenograft tissues. Our results demonstrated that Zol exerts immunomodulatory effects by modulating various immune cell
types, specifically increasing plasma cells (Figure 6). In
the future, the immunomodulatory effects of Zol can be
exploited in conjunction with immune checkpoint
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Figure 6. Cartoon demonstrating Zol-mediated inhibition of FDPS enhancing radiosensitization and potentially exerting immunomodulatory effects by modulating various immune cell types and altering tumour immunity. In PDAC xenograft cells, Zol inhibition
of FDPS exerts local tumour control by reducing prenylation of small GTPases, thereby affecting multiple PDAC-promoting pathways
such as survival and proliferative signalling (AKT and ERK), DNA damage, and DNA repair mechanisms resulting in promoting G2M
arrest and apoptosis. Furthermore, as we observed from PDAC patient's PDMCs, Zol disruption of FDPS leads to accumulation of isopentenyl pyrophosphate (IPP) which activates gamma-delta T cells. Zol reverses the M2 to M1 macrophage phenotype, and activates NK cells. Similarly, in dendritic cells and NK cells co-culture studies, ZOL reduced the endogenous phenyl pyrophosphate
present in antigen-presenting dendritic cells, leading to IL-1b and IL-18 secretion, which activates NK cells to secrete IFN-g. Apart
from these effects on immune components, Zol could exhibit systemic immunomodulatory effects on CD4+ and CD8+ T cells.

inhibitors to improve the efficacy of RT for PDAC
patients. The ongoing Phase I/II study of SBRT with or
without Zol will evaluate the safety and efficacy of Zol
+RT/5FU or capecitabine. Enrollment is ongoing, and
results are anticipated in 2022.
In summary, our studies demonstrate that FDPS is a
viable target to reduce PDAC RR. One of the major innovations of our study is the development of an imageguided animal model for preclinical testing of radiosensitizers for PDAC. Major caveats and limitations related to
the main study includes: (a) prognostic markers that predict Zol’s response in PDAC patients were not identified
yet, (b) small sample size/population enrolled in our clinical trial limits the ability to relate the association of Zol
+RT response and overall and disease-free survival, (c) the
clinical follow-up is short, and the trial has not completed
yet with only interim results, and (d) in vivo studies needs
to be validated in spontaneous KPC mouse models. In
the future, we plan to apply this approach to PDAC
patients harboring oncogenic KRAS in association with
additional
alterations,
i.e.,
p53,
CDKN,
and
SMAD4 mutations/deletions, etc., to predict theefficacy of
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Zol on a specific patient population or subgroup of
PDAC patients. Our work demonstrated the safety and
efficacy of Zol+RT in a single institution randomized
phase I/II clinical study.54 Our work may serve as a stepping stone in establishing an optimal multimodality neoadjuvant PDAC regimen by incorporating combination
chemotherapy, immunotherapy, and RT with Zol.4,55,56
Our study also provides a rationale for applying a similar
radiosensitization approach in other cancers with CBS
pathway dysregulation.

Declaration of interests
Dr. Surinder K. Batra is one of the co-founders of Sanguine Diagnostics and Therapeutics, Inc. All other
authors disclosed no potential conflicts of interest.

Contributors
Study design: PS, CL, and SKB
Experiment performed and data analysis: PS, SH,
RN, SR, SC, PA, RCV, RV, JC, SKG, SW, SL, and GAT
www.thelancet.com Vol xx Month xx, 2021

Articles

Funding acquisition: MJ and SKB
Clinical investigation: KK, Q Ly, BNR, JLG, LB, JCP,
and CL
Data verification: PS, LS, JC, PA, RCV, MPP, S Kaur,
SK, MJ, CL, and SKB
Supervision: CL and SKB
Writing draft manuscript: PS, JC, and LS
Manuscript revision and final proofed: SH, RN, SR, SC,
PA, RCV, MMO, JC, SKG, RV, SW, SL, LS, GAT, KK, Q
Ly, BNR, JLG, LB, JCP, S Kaur, SK, MPP, MJ, CL, and
SKB.
All authors are aware of the data in this paper’s content, read and approved the final version of the manuscript.

6

Data sharing statement

9

The processed transcriptomic data, BAM and FASTQ
files, and corresponding metadata are submitted to
NCBI’s SRA database (Bio project PRJNA739147, Submission-ID: SUB9857194).

4

5

7

8

10

11

Acknowledgments
The work in this article was supported, in parts, by the
following grants from the National Institutes of Health
(P50 CA 127297 (Dr. Batra), P01 CA217798 (Dr. Batra),
R01 CA195586 (Dr. Batra and Dr. Jain), R01 CA247471
(Dr. Batra and Dr. Jain), R01 CA210637 (Dr. Ponnusamy), and U01 CA213862 (Dr. Jain).
We thank Kavita Mallya and Corinn E. Grabow for
their technical help. We also thank Amy Filler-Katz and
Erin L Doherty for their coordination in a clinical study.
We thank Jessica Mercer for the editorial assistance of
this manuscript. We thank the UNMC Sequencing
Core facility for RNA seq. analysis in clinical specimens.
We thank Craig Semerad and Victoria B. Smith of the
Flow Cytometry Research Facility, UNMC, for assisting
with flow cytometry. Schematic figure and cartoons
were created using BioRender.com. Finally, we thank
Janice A. Taylor and James R. Talaska of the Advanced
Microscopy Core Facility at the UNMC for help with
confocal microscopy.

Supplementary materials
Supplementary material associated with this article can
be found in the online version at doi:10.1016/j.
ebiom.2021.103772.
References
1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J
Clin 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.
2 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378(9791):607–20. https://doi.org/10.1016/
S0140-6736(10)62307-0.
3 Chakraborty S, Singh S. Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based
study. Ann Gastroenterol 2013;26(4):346–52.

www.thelancet.com Vol xx Month xx, 2021

12
13

14
15

16

17

18

19

20

21

22

Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, et al.
Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol 2018;4(7):963–9.
https://doi.org/10.1001/jamaoncol.2018.0329.
Seshacharyulu P, Baine MJ, Souchek JJ, Menning M, Kaur S, Yan Y,
et al. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta Rev Cancer
2017;1868(1):69–92. https://doi.org/10.1016/j.bbcan.2017.02.003.
Hall WA, Goodman KA. Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. Radiat Oncol 2019;14(1):114.
https://doi.org/10.1186/s13014-019-1277-1.
Souchek JJ, Baine MJ, Lin C, Rachagani S, Gupta S, Kaur S, et al.
Unbiased analysis of pancreatic cancer radiation resistance reveals
cholesterol biosynthesis as a novel target for radiosensitisation. Br J
Cancer 2014;111(6):1139–49. https://doi.org/10.1038/bjc.2014.385.
Seshacharyulu P, Rachagani S, Muniyan S, Siddiqui JA, Cruz E,
Sharma S, et al. FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT
axis. Oncogene 2019;38(26):5265–80. https://doi.org/10.1038/
s41388-019-0791-9.
Abate M, Laezza C, Pisanti S, Torelli G, Seneca V, Catapano G, et al.
Deregulated expression and activity of farnesyl diphosphate synthase (FDPS) in glioblastoma. Sci Rep 2017;7(1):14123. https://doi.
org/10.1038/s41598-017-14495-6.
Kim HY, Kim DK, Bae SH, Gwak H, Jeon JH, Kim JK, et al. Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness. Exp Mol Med 2018;50(10):1–12. https://doi.org/
10.1038/s12276-018-0166-2.
Notarnicola M, Messa C, Cavallini A, Bifulco M, Tecce MF, Eletto D,
et al. Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology 2004;67(56):351–8. https://doi.org/10.1159/000082918.
Zekri J, Mansour M, Karim SM. The anti-tumour effects of zoledronic acid. J Bone Oncol 2014;3(1):25–35. https://doi.org/10.1016/j.
jbo.2013.12.001.
Jobke B, Milovanovic P, Amling M, Busse B. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by
antiresorptive nitrogen-containing bisphosphonate treatment in
osteoporosis patients. Bone 2014;59:37–43. https://doi.org/10.1016/
j.bone.2013.10.024.
Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of
action and role in clinical practice. Mayo Clin Proc 2008;83
(9):1032–45. https://doi.org/10.4065/83.9.1032.
Sanfilippo KM, Gage B, Luo S, Weilbaecher K, Tomasson M, Vij R,
et al. Comparative effectiveness on survival of zoledronic acid versus
pamidronate in multiple myeloma. Leuk Lymphoma 2015;56(3):615–
21. https://doi.org/10.3109/10428194.2014.924117.
Kaushik G, Seshacharyulu P, Rauth S, Nallasamy P, Rachagani S,
Nimmakayala RK, et al. Selective inhibition of stemness through
EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis.
Oncogene 2020. https://doi.org/10.1038/s41388-020-01564-w.
Boothman DA, Greer S, Pardee AB. Potentiation of halogenated
pyrimidine radiosensitizers in human carcinoma cells by beta-lapachone
(3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran5,6dione), a novel DNA repair inhibitor. Cancer Res 1987;47(20):5361–
6.
Hein AL, Post CM, Sheinin YM, Lakshmanan I, Natarajan A, Enke
CA, et al. RAC1 GTPase promotes the survival of breast cancer cells
in response to hyper-fractionated radiation treatment. Oncogene
2016;35(49):6319–29. https://doi.org/10.1038/onc.2016.163.
Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012;7(3):562–78.
https://doi.org/10.1038/nprot.2012.016.
Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan
K, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment
in pancreatic cancer. Gut 2017;66(1):124–36. https://doi.org/
10.1136/gutjnl-2016-312078.
Lakshmanan I, Ponnusamy MP, Das S, Chakraborty S, Haridas D,
Mukhopadhyay P, et al. MUC16 induced rapid G2/M transition via
interactions with JAK2 for increased proliferation and anti-apoptosis
in breast cancer cells. Oncogene 2012;31(7):805–17. https://doi.org/
10.1038/onc.2011.297.
Ricoult SJ, Yecies JL, Ben-Sahra I, Manning BD. Oncogenic PI3K
and K-Ras stimulate de novo lipid synthesis through mTORC1 and

19

Articles

23

24

25

26

27

28

29

30
31
32

33

34

35

36

37

38

39

40

20

SREBP. Oncogene 2016;35(10):1250–60. https://doi.org/10.1038/
onc.2015.179.
Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK,
Batra SK. Targeting the EGFR signaling pathway in cancer therapy.
Expert Opin Ther Targets 2012;16(1):15–31. https://doi.org/10.1517/
14728222.2011.648617.
Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM,
Poulter CD, et al. Structure-activity relationships for inhibition of
farnesyl diphosphate synthase in vitro and inhibition of bone
resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296(2):235–42.
Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther 2020;5(1):288.
https://doi.org/10.1038/s41392-020-00361-x.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM,
Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149(5):1060–72. https://doi.org/10.1016/j.
cell.2012.03.042.
Cardama GA, Alonso DF, Gonzalez N, Maggio J, Gomez DE, Rolfo
C, et al. Relevance of small GTPase Rac1 pathway in drug and radioresistance mechanisms: opportunities in cancer therapeutics. Crit
Rev Oncol Hematol 2018;124:29–36. https://doi.org/10.1016/j.critrevonc.2018.01.012.
Pickering KA, Gilroy K, Cassidy JW, Fey SK, Najumudeen AK,
Zeiger LB, et al. A RAC-GEF network critical for early intestinal
tumourigenesis. Nature Communications 2021;12(1):56. https://doi.
org/10.1038/s41467-020-20255-4.
Bid HK, Roberts RD, Manchanda PK, Houghton PJ. RAC1: an
emerging therapeutic option for targeting cancer angiogenesis and
metastasis. Mol Cancer Ther 2013;12(10):1925–34. https://doi.org/
10.1158/1535-7163.MCT-13-0164.
Zhao Y, Niu C, Cui J. Gamma-delta (gammadelta) T cells: friend or
foe in cancer development? J Transl Med 2018;16(1):3. https://doi.
org/10.1186/s12967-017-1378-2.
Kuzu OF, Noory MA, Robertson GP. The role of cholesterol in cancer. Cancer Res 2016;76(8):2063–70. https://doi.org/10.1158/00085472.CAN-15-2613.
Zhao Y, Wu TY, Zhao MF, Li CJ. The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic
fatty liver disease. J Biol Chem 2020;295(15):5152–62. https://doi.
org/10.1074/jbc.REV119.008897.
Wu CY, Carpenter ES, Takeuchi KK, Halbrook CJ, Peverley LV, Bien
H, et al. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. Gastroenterology 2014;147(6):1405-16
e7. https://doi.org/10.1053/j.gastro.2014.08.032.
Cox AD, Der CJ, Philips MR. Targeting RAS membrane association:
back to the future for anti-RAS Drug discovery? Clin Cancer Res
https://doi.org/10.1158/1078-0432.CCR-142015;21(8):1819–27.
3214.
Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave
ME, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004;64(6):2212–21.
https://doi.org/10.1158/0008-5472.can-2148-2.
Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, GonzalezBillalabeitia E, et al. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nat Genet 2018;50
(2):206–18. https://doi.org/10.1038/s41588-017-0027-2.
Wiemer AJ, Tong H, Swanson KM, Hohl RJ. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochem Biophys Res Commun 2007;353(4):921–5. https://doi.org/10.1016/j.
bbrc.2006.12.094.
Tang Q, Jiang S, Jia W, Shen D, Qiu Y, Zhao Y, et al. Zoledronic
acid, an FPPS inhibitor, ameliorates liver steatosis through inhibiting hepatic de novo lipogenesis. Eur J Pharmacol 2017;814:169–77.
https://doi.org/10.1016/j.ejphar.2017.08.010.
Misra J, Mohanty ST, Madan S, Fernandes JA, Hal Ebetino F, Russell RG, et al. Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function. Stem
Cells 2016;34(3):756–67. https://doi.org/10.1002/stem.2255.
Ural AU, Avcu F, Candir M, Guden M, Ozcan MA. In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast

41
42

43

44

45

46
47

48

49

50

51

52

53
54

55

56

cancer cells. Breast Cancer Res 2006;8(4):R52. https://doi.org/
10.1186/bcr1543.
Ryu K, Murata H, Koto K, Horie N, Matsui T, Nishigaki Y, et al.
Combined effects of bisphosphonate and radiation on osteosarcoma
cells. Anticancer Res 2010;30(7):2713–20.
Du C, Wang Y, Li H, Huang Y, Jiang O, You Y, et al. Zoledronic acid
augments the radiosensitivity of cancer cells through perturbing Sand M-phase cyclins and p21(CIP1) expression. Oncol Lett 2017;14
(4):4237–42. https://doi.org/10.3892/ol.2017.6710.
Paillas S, Then CK, Kilgas S, Ruan JL, Thompson J, Elliott A, et al.
The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder
Tumors in Vivo. Int J Radiat Oncol Biol Phys 2020;107(1):212–21.
https://doi.org/10.1016/j.ijrobp.2020.01.015.
Groselj B, Ruan JL, Scott H, Gorrill J, Nicholson J, Kelly J, et al.
Radiosensitization in vivo by histone deacetylase inhibition with no
increase in early normal tissue radiation toxicity. Mol Cancer Ther
2018;17(2):381–92. https://doi.org/10.1158/1535-7163.MCT-17-0011.
Tchelebi LT, Zaorsky NG, Rosenberg JC, Sharma NK, Tuanquin LC,
Mackley HB, et al. Reducing the Toxicity of Radiotherapy for Pancreatic Cancer With Magnetic Resonance-guided Radiotherapy. Toxicol Sci 2020;175(1):19–23. https://doi.org/10.1093/toxsci/kfaa021.
Nair AB, Jacob S. A simple practice guide for dose conversion
between animals and human. J Basic Clin Pharm 2016;7(2):27–31.
https://doi.org/10.4103/0976-0105.177703.
Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, et al.
Organoid models of human and mouse ductal pancreatic cancer.
Cell
2015;160(1-2):324–38.
https://doi.org/10.1016/j.
cell.2014.12.021.
Varela I, Pereira S, Ugalde AP, Navarro CL, Suarez MF, Cau P, et al.
Combined treatment with statins and aminobisphosphonates
extends longevity in a mouse model of human premature aging.
Nat Med 2008;14(7):767–72. https://doi.org/10.1038/nm1786.
George CN, Canuas-Landero V, Theodoulou E, Muthana M, Wilson
C, Ottewell P. Oestrogen and zoledronic acid driven changes to the
bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in preand post-menopausal conditions. J Bone Oncol 2020;25:100317.
https://doi.org/10.1016/j.jbo.2020.100317.
Merli P, Algeri M, Galaverna F, Milano GM, Bertaina V, Biagini S,
et al. Immune modulation properties of zoledronic acid on tcrgammadelta t-lymphocytes after TcRalphabeta/CD19-Depleted haploidentical stem cell transplantation: an analysis on 46 pediatric
patients affected by. Acute Leukemia Front Immunol 2020;11:699.
https://doi.org/10.3389/fimmu.2020.00699.
Liu H, Wang SH, Chen SC, Chen CY, Lo JL, Lin TM. Immune modulation of CD4(+)CD25(+) regulatory T cells by zoledronic acid.
BMC Immunol 2016;17(1):45. https://doi.org/10.1186/s12865-0160183-7.
Weber M, Homm A, Muller S, Frey S, Amann K, Ries J, et al.
Zoledronate causes a systemic shift of macrophage polarization
towards M1 in vivo. Int J Mol Sci 2021;22(3). https://doi.org/
10.3390/ijms22031323.
Narayanan V, Weekes CD. Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol 2016;8(4):366–79. https://doi.org/
10.4251/wjgo.v8.i4.366.
Murphy AG, Zahurak M, Shah M, Weekes CD, Hansen A, Siu LL,
et al. A phase I study of dinaciclib in combination with MK-2206 in
patients with advanced pancreatic cancer. Clin Transl Sci 2020;13
(6):1178–88. https://doi.org/10.1111/cts.12802.
Tabernero J, Kunzmann V, Scheithauer W, Reni M, Shiansong Li J,
Ferrara S, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort
of the MPACT trial. Onco Targets Ther 2017;10:591–6. https://doi.
org/10.2147/OTT.S124097.
Michelakos T, Cai L, Villani V, Sabbatino F, Kontos F, FernandezDel Castillo C, et al. Tumor microenvironment immune response
in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy. J Natl Cancer Inst 2020. https://doi.org/10.1093/jnci/
djaa073.

www.thelancet.com Vol xx Month xx, 2021

